Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patient... | NCT02001623 | Trialant
NCT02001623
Sponsor
Seagen Inc.
Status
Completed
Last Update Posted
Dec 29, 2021Actual
Enrollment
195Actual
Phase
Phase 1Phase 2
Conditions
Ovary Cancer
Cervix Cancer
Endometrium Cancer
Bladder Cancer
Prostate Cancer (CRPC)
Esophagus Cancer
Lung Cancer(NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)
Countries
United States
Belgium
Denmark
Sweden
United Kingdom
Protocol Section
Identification Module
NCT ID
NCT02001623
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
GEN701
Secondary IDs
ID
Type
Description
Link
innovaTV 201
Other Identifier
Genmab
Brief Title
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Official Title
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Acronym
Not provided
Organization
Seagen Inc.INDUSTRY
Status Module
Record Verification Date
Nov 2021
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Nov 30, 2013Actual
Primary Completion Date
May 2, 2019Actual
Completion Date
May 2, 2019Actual
First Submitted Date
Nov 14, 2013
First Submission Date that Met QC Criteria
Nov 28, 2013
First Posted Date
Dec 5, 2013Estimated
Results Waived
Not provided
Results First Submitted Date
Oct 6, 2021
Results First Submitted that Met QC Criteria
Nov 29, 2021
Results First Posted Date
Dec 29, 2021Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Apr 21, 2020
Certification/Extension First Submitted that Passed QC Review
Apr 21, 2020
Certification/Extension First Posted Date
Apr 24, 2020Actual
Last Update Submitted Date
Nov 29, 2021
Last Update Posted Date
Dec 29, 2021Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Seagen Inc.INDUSTRY
Collaborators
Name
Class
Genmab
INDUSTRY
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Detailed Description
The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.
In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of HuMax-TF-ADC as determined in Part 1
Conditions Module
Conditions
Ovary Cancer
Cervix Cancer
Endometrium Cancer
Bladder Cancer
Prostate Cancer (CRPC)
Esophagus Cancer
Lung Cancer(NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Keywords
ovary cancer
cervix cancer
endometrium cancer
bladder cancer
prostate cancer (CRPC)
esophagus cancer
lung cancer(NSCLC)
Squamous cell carcinoma of the head and neck (SCCHN)
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
195Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Tisotumab Vedotin (HuMax-TF-ADC)
Experimental
All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
Drug: Tisotumab Vedotin (HuMax-TF-ADC)
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Tisotumab Vedotin (HuMax-TF-ADC)
Drug
Tisotumab Vedotin (HuMax-TF-ADC)
TIVDAK
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one:
TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade >=3 Treatment-related TEAE
A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one:
TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade >=3 Treatment-related TEAE
A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.
Secondary Outcomes
Measure
Description
Time Frame
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values
Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade >= 3 hematology value.
A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
- Patients with relapsed, advanced and/or metastatic cancer who have failed available standard treatments or who are not candidates for standard therapy.
Patients must have measurable disease
Age ≥ 18 years.
Acceptable renal function
Acceptable liver function
Acceptable hematological status (without hematologic support
Acceptable coagulation status
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of at least three months.
A negative serum pregnancy test (if female and aged between 18-55 years old).
Women who are pregnant or breast feeding are not to be included.
Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.
Following receipt of verbal and written information about the study, patients must provide signed informed consent before any study-related activity is carried out.
Exclusion Criteria:
Known past or current coagulation defects.
Ongoing major bleeding,
Have clinically significant cardiac disease
A baseline QT interval as corrected by Fridericia's formula (QTcF) > 450 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.
Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within one week or pegylated G-CSF within two weeks before the Screening Visit.
Have received a cumulative dose of corticosteroid ≥ 100 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
Major surgery within six weeks or open biopsy within 14 days before drug infusion.
Plan for any major surgery during treatment period.
Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain metastases or stroke.
Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
Prior treatment with bevacizumab within twelve weeks before the first infusion.
Radiotherapy within 28 days prior to first dose.
Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
Known past or current malignancy other than inclusion diagnosis, except for:
Cervical carcinoma of Stage 1B or less.
Non-invasive basal cell or squamous cell skin carcinoma.
Non-invasive, superficial bladder cancer.
Prostate cancer with a current PSA level < 0.1 ng/mL.
Any curable cancer with a complete response (CR) of > 5 years duration.
Known human immunodeficiency virus seropositivity.
Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for hepatitis B
Positive serology for hepatitis C based on test at screening.
Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
Ongoing acute or chronic inflammatory skin disease.
Accepts Healthy Volunteers
No
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
Not provided
Standard Ages
AdultOlder Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Name
Affiliation
Role
Johann de Bono, Professor
The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Principal Investigator
Locations
Facility
Status
City
State
ZIP
Country
Contacts
University of California Irvine Medical Center (UCIMC)
In the dose escalation part of the study, 40 participants were screened and 27 were enrolled and received treatment. In the dose expansion part of the study, 294 participants were screened and 168 were enrolled and received treatment.
Recruitment Details
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
FG001
Dose Escalation Part: 0.6 mg/kg
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot
Yes
No
No
Study Protocol
Jul 18, 2018
Oct 6, 2021
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
N/A
Intervention Model
Sequential Assignment
Intervention Model Description
Escalation phase for dose finding followed by expansion phase
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values
Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade >= 3 coagulation value.
A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values
Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade >= 3 biochemistry value.
A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest
Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ [20000039] (Broad) and Haemorrhage, laboratory terms SMQ [20000040] (Narrow).
Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included.
Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event
Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below.
Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF
Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: AUC0-inf of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Cmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Tmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin
Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage
Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements
Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)
PSA was only assessed in participants with castrate-resistant prostate cancer.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125
In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Objective Response Rate
Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Disease Control Rate
Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.
At 6, 12, 24 and 36 weeks
Dose Escalation and Expansion Part: Progression Free Survival (PFS)
PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions
Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Expansion Part: Duration of Response (DOR)
DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.
Day 1 to end of follow-up, up to a maximum of 60 weeks
Yale Cancer Center
New Haven
Connecticut
06520
United States
University of Miami
Miami
Florida
33136
United States
University Gynecologic Oncology
Atlanta
Georgia
30342
United States
Comprehensive Cancer Centers of Nevada
Las Vegas
Nevada
89169
United States
Sarah Cannon Research Institute
Nashville
Tennessee
37203
United States
MD Anderson Cancer Center
Houston
Texas
77030
United States
University of Virginia
Charlottesville
Virginia
22908
United States
Universitair Ziekenhuis Antwerpen
Edegem
Antwerpen
2650
Belgium
Universitair Ziekenhuis Leuven
Leuven
Flemish Brabant
3000
Belgium
Grand Hôpital de Charleroi
Charleroi
Hainaut
6000
Belgium
Centre Hospitalier Universitaire Ambroise Paré
Mons
Hainaut
7000
Belgium
CHU UCL Namur - site Godinne
Yvoir
Namur
5530
Belgium
Saint-Luc University Hospital
Brussels
1200
Belgium
CHU de Liège
Liège
4000
Belgium
CHU UCL Namur - Sainte Elisabeth
Namur
5000
Belgium
Rigshospitalet, Copenhagen University Hospital
Copenhagen
DK-2100
Denmark
Herlev and Gentofte Hospital
Herlev
2730
Denmark
Karolinska Universitetssjukhuset
Stockholm
Solna
17176
Sweden
Lungemedicinska Kliniken
Linköping
58185
Sweden
The Leeds Teaching Hospitals NHS Trust
Leeds
England
LS9 7TF
United Kingdom
University College London Hospitals
London
England
NW1 2BU
United Kingdom
Sarah Cannon Research Institute - London
London
England
W1G 6AD
United Kingdom
Newcastle Hospitals NHS Foundation Trust
Newcastle upon Tyne
Newcastle
NE7 7DN
United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton
Surrey
SM2 5PT
United Kingdom
Velindre NHS Trust
Cardiff
Wales
CF14 2TL
United Kingdom
Beatson Cancer Centre
Glasgow
G12 OYN
United Kingdom
Guys hospital
London
SE1 9RT
United Kingdom
The Christie NHS Foundation Trust
Manchester
M20 4BX
United Kingdom
Derived
Feng S, Gunawan R, Passey C, Voellinger J, Polhamus D, Gerritsen A, O'Day C, Carret AS, Soumaoro I, Gupta M, Hanley WD. Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin. J Pharmacokinet Pharmacodyn. 2025 Oct 3;52(5):55. doi: 10.1007/s10928-025-10003-w.
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3.
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
FG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
FG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
FG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
FG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
FG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
FG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0033 subjects
FG0043 subjects
FG0053 subjects
FG0063 subjects
FG0076 subjects
FG00815 subjects
FG00955 subjects
FG01014 subjects
FG01115 subjects
FG01215 subjects
FG01336 subjects
FG01418 subjects
Completed 4 Cycles of Treatment
FG0000 subjects
FG0011 subjects
FG0021 subjects
FG0032 subjects
FG0040 subjects
FG0052 subjects
FG0062 subjects
FG0071 subjects
FG0085 subjects
FG00931 subjects
FG0106 subjects
FG0114 subjects
FG0126 subjects
FG01322 subjects
FG0147 subjects
Completed 12 Cycles of Treatment
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0031 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0093 subjects
FG0100 subjects
FG0110 subjects
FG0121 subjects
FG0131 subjects
FG0140 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0092 subjects
FG0100 subjects
FG0110 subjects
FG0121 subjects
FG0131 subjects
FG0140 subjects
NOT COMPLETED
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0032 subjects
FG0043 subjects
FG0053 subjects
FG0063 subjects
FG0076 subjects
FG00815 subjects
FG00953 subjects
FG01014 subjects
FG01115 subjects
FG01214 subjects
FG01335 subjects
FG01418 subjects
Type
Comment
Reasons
Disease Progression
FG0002 subjects
FG0012 subjects
FG0023 subjects
FG0032 subjects
FG0043 subjects
FG0052 subjects
FG0063 subjects
FG0073 subjects
FG0087 subjects
FG00940 subjects
FG0105 subjects
FG0119 subjects
FG0129 subjects
FG01320 subjects
FG0149 subjects
Physician Decision
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Death
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG004
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Other - Miscellaneous
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Start of New Anti-cancer Treatment
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Dose Delay Due to Toxicity
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
BG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
BG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
BG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
BG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
BG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
BG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
BG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
BG015
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0003
BG0013
BG0023
BG0033
BG0043
BG0053
BG0063
BG0076
BG00815
BG00955
BG01014
BG01115
BG01215
BG01336
BG01418
BG015195
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Customized
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
In utero
BG0000
BG0010
BG0020
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0001
BG0011
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0010
BG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
White
BG0003
BG0013
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one:
TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade >=3 Treatment-related TEAE
A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
TEAEs
Title
Measurements
OG0003
OG0013
OG0023
OG003
Secondary
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values
Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade >= 3 hematology value.
A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values
Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade >= 3 coagulation value.
A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values
Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade >= 3 biochemistry value.
A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest
Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ [20000039] (Broad) and Haemorrhage, laboratory terms SMQ [20000040] (Narrow).
Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included.
Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event
Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below.
Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Secondary
Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF
Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
mL/hr/kg
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
mL/kg
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
day*ug/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
day*ug/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
ug/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
hours
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
hours
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
day*ng/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: AUC0-inf of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose
Posted
Geometric Mean
Geometric Coefficient of Variation
day*ng/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Cmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose
Posted
Geometric Mean
Geometric Coefficient of Variation
ng/mL
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Tmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
hours
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.
PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.
Posted
Geometric Mean
Geometric Coefficient of Variation
hours
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin
Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.
Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage
Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.
Full analysis set: all participants who had been exposed to tisotumab vedotin in the dose escalation part.
Posted
Count of Participants
Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Primary
Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one:
TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade >=3 Treatment-related TEAE
A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Posted
Count of Participants
Participants
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.
ID
Title
Description
OG000
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG001
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Secondary
Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements
Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.
The number of participants analyzed includes all participants with baseline and one post-baseline evaluable tumor assessment
Posted
Median
Full Range
millimeter(s)
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG001
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG002
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)
PSA was only assessed in participants with castrate-resistant prostate cancer.
Analyses includes all participants with castrate-resistant prostate cancer who have a baseline and end of study evaluable assessment.
Posted
Median
Full Range
Percentage Change in PSA
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Secondary
Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125
In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.
Analyses includes all participants in the dose escalation and expansion parts with ovarian cancer and some participants with NSCLC and cervical cancer in the dose expansion part who have a baseline and end of study evaluable assessment.
Posted
Median
Full Range
Percentage Change
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Secondary
Dose Escalation and Expansion Part: Objective Response Rate
Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.
Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.
Posted
Number
95% Confidence Interval
Percentage of Participants
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Part: Disease Control Rate
Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.
Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.
Posted
Number
95% Confidence Interval
Percentage of Participants
At 6, 12, 24 and 36 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Escalation and Expansion Part: Progression Free Survival (PFS)
PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions
Participants with documented disease progression and/or death are included.
Posted
Median
95% Confidence Interval
Weeks
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Secondary
Dose Expansion Part: Duration of Response (DOR)
DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.
All participants who had a confirmed response of either CR or PR and were considered a responder for the study.
Posted
Median
95% Confidence Interval
Weeks
Day 1 to end of follow-up, up to a maximum of 60 weeks
ID
Title
Description
OG000
Dose Escalation Part: 0.3 mg/kg
Dose Escalation Part: 0.3 mg/kgEdit Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
OG001
Dose Escalation Part: 0.6 mg/kg
Dose Escalation Part: 0.6 mg/kgEdit Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
OG002
Dose Escalation Part: 0.9 mg/kg
Dose Escalation Part: 0.9 mg/kgEdit Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
Time Frame
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the escalation part and from 1 to 325 days in the expansion part.
Description
Deaths from all causes are reported from day of enrollment to end of follow up (up to maximum of 60 weeks).
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Dose Escalation Part: 0.3 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.
2
3
2
3
3
3
EG001
Dose Escalation Part: 0.6 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.
1
3
1
3
3
3
EG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
0
3
0
3
3
3
EG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
0
3
2
3
3
3
EG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
0
3
2
3
3
3
EG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
0
3
2
3
3
3
EG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
0
3
2
3
3
3
EG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
0
6
4
6
6
6
EG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
0
15
7
15
15
15
EG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
2
55
26
55
55
55
EG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
0
14
5
14
14
14
EG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
1
15
8
15
15
15
EG012
Dose Expansion Part: Non-Small-Cell Lung Cancer
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
1
15
6
15
15
15
EG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
2
36
13
36
36
36
EG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
1
18
6
18
18
18
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Vomiting
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG0030 events0 affected3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
Abdominal pain
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Colitis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastrointestinal haemorrhage
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastrointestinal ulcer haemorrhage
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oesophageal perforation
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Small intestinal obstruction
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Subileus
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Intestinal obstruction
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ascites
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctivitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sepsis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Bacterial sepsis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cellulitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Clostridium difficile colitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Kidney infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Micrococcus infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neutropenic sepsis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Respiratory tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Staphylococcal infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urosepsis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cystitis escherichia
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Klebsiella infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Malaise
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pyrexia
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
General physical health deterioration
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Catheter site pain
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Mucosal inflammation
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Fatigue
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Peripheral sensorimotor neuropathy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cerebrovascular accident
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Guillain-barre syndrome
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Headache
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ischaemic stroke
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lethargy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neuropathy peripheral
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Diabetes mellitus inadequate control
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypoglycaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Diabetes mellitus
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Anaemia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Febrile neutropenia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haematuria
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urinary tract obstruction
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Acute kidney injury
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Malignant neoplasm progression
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oesophageal cancer metastatic
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tumour pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vaginal haemorrhage
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Female genital tract fistula
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypoxia
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pharyngeal haemorrhage
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Transaminases increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Supraventricular extrasystoles
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypoacusis
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperbilirubinaemia
Hepatobiliary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypersensitivity
Immune system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Stress fracture
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Stent malfunction
Product Issues
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vascular disorders
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Large intestinal obstruction
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Device related infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Bile duct obstruction
Hepatobiliary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG0030 events0 affected3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
Hepatitis
Hepatobiliary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ear congestion
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ear pain
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypoacusis
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vertigo
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tinnitus
Ear and labyrinth disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Atrial fibrillation
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pericardial effusion
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sinus tachycardia
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Bradycardia
Cardiac disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tumour pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Melanocytic naevus
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypersensitivity
Immune system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Contrast media allergy
Immune system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Seasonal allergy
Immune system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vaginal haemorrhage
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Balanoposthitis
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Metrorrhagia
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Testicular pain
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vulvovaginal dryness
Reproductive system and breast disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Fall
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival scar
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eyelid contusion
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pharynx radiation injury
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Skin laceration
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sunburn
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Chemical burns of eye
Injury, poisoning and procedural complications
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Flushing
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypotension
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypertension
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hot flush
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Intermittent claudication
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lymphoedema
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Orthostatic hypotension
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Phlebitis
Vascular disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Renal pain
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urine flow decreased
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haematuria
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Proteinuria
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urinary hesitation
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Renal impairment
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysuria
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hydronephrosis
Renal and urinary disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0023 events1 affected3 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0002 events2 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0023 events1 affected3 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Stomatitis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0024 events2 affected3 at risk
EG003
Abdominal discomfort
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rectal haemorrhage
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Abdominal pain lower
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Colitis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gingival bleeding
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ascites
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0004 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cheilitis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Flatulence
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haematemesis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haematochezia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haemorrhoids
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Melaena
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Mouth ulceration
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oesophageal mucosal hyperplasia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oesophagitis
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oral pain
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Proctalgia
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tongue ulceration
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Salivary hypersecretion
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nasal congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysphonia
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rhinorrhoea
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haemoptysis
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nasal inflammation
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nasal obstruction
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Productive cough
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Catarrh
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dry throat
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dyspnoea exertional
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hiccups
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Laryngeal inflammation
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nasal crusting
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pulmonary haemorrhage
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rales
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sinus pain
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sneezing
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pleural effusion
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Paranasal sinus hypersecretion
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pneumonia aspiration
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pneumonitis
Respiratory, thoracic and mediastinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Fatigue
General disorders
MedDRA 22.0
Systematic Assessment
EG0003 events3 affected3 at risk
EG0013 events1 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Pyrexia
General disorders
MedDRA 22.0
Systematic Assessment
EG0004 events2 affected3 at risk
EG0010 events0 affected3 at risk
EG0022 events1 affected3 at risk
EG003
Mucosal inflammation
General disorders
MedDRA 22.0
Systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Oedema peripheral
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Chills
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Malaise
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Asthenia
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Chest pain
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Influenza like illness
General disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pain
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Peripheral swelling
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Chest discomfort
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Face oedema
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gait disturbance
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Infusion site reaction
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Swelling
General disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oedema
General disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Alopecia
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dry skin
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash maculo-papular
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0003 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nail disorder
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Night sweats
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Acne
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Skin hyperpigmentation
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash macular
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dermatitis
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dermatitis acneiform
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Erythema
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperhidrosis
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nail ridging
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Onycholysis
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pain of skin
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Palmar-plantar erythrodysaesthesia syndrome
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash pruritic
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Skin ulcer
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Toxic skin eruption
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urticaria
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Decubitus ulcer
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Skin lesion
Skin and subcutaneous tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctivitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oral herpes
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Oral candidiasis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Rash pustular
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Influenza
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Bronchitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Candida infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Catheter site infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctivitis bacterial
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cystitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eye infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gingivitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haemophilus infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Skin infection
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tooth abscess
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cellulitis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Urethritis
Infections and infestations
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neuropathy peripheral
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events1 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Peripheral sensory neuropathy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Headache
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Lethargy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dizziness
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0013 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysgeusia
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Peripheral motor neuropathy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Polyneuropathy
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Tremor
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Migraine
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Taste disorder
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Balance disorder
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ataxia
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Brain oedema
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Carpal tunnel syndrome
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Central pain syndrome
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dysaesthesia
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Mental impairment
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Myoclonus
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Nerve compression
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sciatica
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Spinal cord compression
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Amputation stump pain
Nervous system disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events2 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypomagnesaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dehydration
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypocalcaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperuricaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypoalbuminaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypophosphataemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Iron deficiency
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vitamin d deficiency
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hyperkalaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0013 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0012 events2 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Bone pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Bursitis
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Muscle atrophy
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Musculoskeletal stiffness
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Arthritis climacteric
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Joint swelling
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Dry eye
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lacrimation increased
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blepharitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vision blurred
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival ulcer
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Keratitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Meibomianitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Noninfective conjunctivitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Symblepharon
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eye pain
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ocular hyperaemia
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Cataract
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival hyperaemia
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Ulcerative keratitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival disorder
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Foreign body sensation in eyes
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival haemorrhage
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eye pruritus
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Punctate keratitis
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Chorioretinopathy
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Open angle glaucoma
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Periorbital oedema
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Retinal vein occlusion
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eye inflammation
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Eye irritation
Eye disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Weight decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Blood alkaline phosphatase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Gamma-glutamyltransferase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Vital dye staining cornea present
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
White blood cell count decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood creatine phosphokinase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Haemoglobin decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Platelet count decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lymphocyte count decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neutrophil count decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood magnesium decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood potassium increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood urea increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood urine present
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Body temperature increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Conjunctival staining
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Transaminases increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood fibrinogen increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Serum ferritin increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Activated partial thromboplastin time prolonged
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood lactate dehydrogenase increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Blood urea decreased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
C-reactive protein increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Fibrin d dimer increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Neutrophil count increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
White blood cell count increased
Investigations
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Anaemia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0013 events3 affected3 at risk
EG0022 events1 affected3 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lymph node pain
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Lymphadenopathy
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected3 at risk
EG003
Neutrophilia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Febrile neutropenia
Blood and lymphatic system disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Depressed mood
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Depression
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Confusional state
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Mood altered
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Panic attack
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Restlessness
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Sleep disorder
Psychiatric disorders
MedDRA 22.0
Systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Hypercalcaemia
Metabolism and nutrition disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 22.0
Systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected3 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
All proposed publications and presentations shall be submitted to the sponsor for its review at least 30 days before such presentation or publication is submitted to any third party.
Female Urogenital Diseases and Pregnancy Complications
D000091642
Urogenital Diseases
D005833
Genital Neoplasms, Female
D014565
Urogenital Neoplasms
D000091662
Genital Diseases
D004700
Endocrine System Diseases
D006058
Gonadal Disorders
D014594
Uterine Neoplasms
D002577
Uterine Cervical Diseases
D014591
Uterine Diseases
D014571
Urologic Neoplasms
D001745
Urinary Bladder Diseases
D014570
Urologic Diseases
D052801
Male Urogenital Diseases
D005834
Genital Neoplasms, Male
D005832
Genital Diseases, Male
D011469
Prostatic Diseases
D005770
Gastrointestinal Neoplasms
D004067
Digestive System Neoplasms
D006258
Head and Neck Neoplasms
D004066
Digestive System Diseases
D004935
Esophageal Diseases
D005767
Gastrointestinal Diseases
D002294
Carcinoma, Squamous Cell
D002277
Carcinoma
D009375
Neoplasms, Glandular and Epithelial
D009370
Neoplasms by Histologic Type
Browse Leaves
Not provided
Browse Branches
Not provided
ID
Term
C000707142
tisotumab vedotin
Ancestor Terms
Not provided
Browse Leaves
Not provided
Browse Branches
Not provided
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0083 subjects
FG0092 subjects
FG0103 subjects
FG0113 subjects
FG0121 subjects
FG0132 subjects
FG0141 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
0 subjects
FG0051 subjects
FG0060 subjects
FG0073 subjects
FG0084 subjects
FG0096 subjects
FG0104 subjects
FG0110 subjects
FG0123 subjects
FG0135 subjects
FG0146 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0091 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0131 subjects
FG0140 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0081 subjects
FG0093 subjects
FG0102 subjects
FG0112 subjects
FG0121 subjects
FG0135 subjects
FG0142 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0091 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0111 subjects
FG0120 subjects
FG0131 subjects
FG0140 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0131 subjects
FG0140 subjects
0
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Preterm newborn infants (gestational age < 37 wks)
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Newborns (0-27 days)
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Infants and toddlers (28 days-23 months)
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Children (2-11 years)
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Adolescents (12-17 years)
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Adults (18-64 years)
BG0003
BG0011
BG0023
BG0033
BG0042
BG0052
BG0062
BG0074
BG00812
BG00951
BG0108
BG0118
BG0129
BG01326
BG0144
BG015138
From 65-84 years
BG0000
BG0012
BG0020
BG0030
BG0041
BG0051
BG0061
BG0072
BG0083
BG0094
BG0106
BG0117
BG0126
BG01310
BG01414
BG01557
85 years and over
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
1
BG0032
BG0042
BG0053
BG0063
BG0075
BG0082
BG00955
BG01014
BG0113
BG01212
BG01336
BG0140
BG015140
Male
BG0002
BG0012
BG0022
BG0031
BG0041
BG0050
BG0060
BG0071
BG00813
BG0090
BG0100
BG01112
BG0123
BG0130
BG01418
BG01555
0
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0101
BG0110
BG0120
BG0131
BG0140
BG0152
Not Hispanic or Latino
BG0003
BG0013
BG0023
BG0033
BG0043
BG0053
BG0063
BG0076
BG00815
BG00953
BG01013
BG01115
BG01215
BG01335
BG01418
BG015191
Unknown or Not Reported
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0092
BG0100
BG0110
BG0120
BG0130
BG0140
BG0152
3
BG0033
BG0043
BG0053
BG0063
BG0076
BG00815
BG00949
BG01014
BG01113
BG01213
BG01334
BG01417
BG015182
Black or Asian American
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0091
BG0100
BG0110
BG0120
BG0130
BG0141
BG0152
Asian
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0093
BG0100
BG0111
BG0121
BG0130
BG0140
BG0155
American Indian or Alaska Native
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0120
BG0130
BG0140
BG0150
Native Hawaiian or other Pacific Islander
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0110
BG0121
BG0130
BG0140
BG0151
Other
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
BG0100
BG0111
BG0120
BG0131
BG0140
BG0152
Missing
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0092
BG0100
BG0110
BG0120
BG0131
BG0140
BG0153
3
OG0043
OG0053
OG0063
OG0076
3
OG0043
OG0053
OG0063
OG0076
Serious TEAEs
Title
Measurements
OG0002
OG0011
OG0020
OG0032
OG0042
OG0052
OG0062
OG0074
Infusion-Related TEAEs
Title
Measurements
OG0001
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0070
CTCAE Grade >=3 TEAEs
Title
Measurements
OG0002
OG0013
OG0021
OG0031
OG0042
OG0053
OG0062
OG0074
TEAEs Related to Study Drug
Title
Measurements
OG0003
OG0013
OG0022
OG0033
OG0043
OG0053
OG0063
OG0076
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0002
OG0011
OG0021
OG0030
OG0042
OG0052
OG0060
OG0071
OG0080
OG00923
OG0100
OG0113
OG0121
OG0135
OG0143
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0071
OG0081
OG0097
OG0102
OG0110
OG0122
OG0135
OG0144
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0002
OG0011
OG0023
OG0030
OG0041
OG0050
OG0061
OG0072
OG0084
OG0098
OG0104
OG0116
OG0122
OG0139
OG0144
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0001
OG0010
OG0020
OG0032
OG0040
OG0052
OG0062
OG0074
OG0083
OG0096
OG0102
OG0112
OG0122
OG0138
OG0145
OG002
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0000
OG0011
OG0020
OG0033
OG0043
OG0053
OG0062
OG0075
OG00810
OG00931
OG01010
OG0117
OG0129
OG01327
OG01410
Dose Escalation Part: 0.9 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0000
OG0011
OG0021
OG0031
OG0040
OG0051
OG0060
OG0071
OG0085
OG00917
OG0106
OG0113
OG0125
OG01317
OG0147
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0075
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0075
Title
Measurements
OG0011.61± 7.79
OG0021.46± 15.23
OG0031.07± 11.60
OG004
Tisotumab Vedotin: Cycle 2
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0075
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0075
Title
Measurements
OG00168.40± 11.84
OG00270.80± 14.54
OG00363.46± 16.87
OG004
Tisotumab Vedotin: Cycle 2
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008167
Title
Measurements
OG0002.5± 3.1
OG00115.4± 8.2
OG00225.1± 16.9
OG003
Tisotumab Vedotin: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
Title
Measurements
OG00115.57± 7.81
OG00225.77± 15.70
OG00346.68± 10.99
OG004
Tisotumab Vedotin: Cycle 2
ParticipantsOG0000
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0000
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008167
Title
Measurements
OG0004.78± 12.35
OG00112.20± 9.47
OG00219.81± 17.32
OG003
Tisotumab Vedotin: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008167
Title
Measurements
OG0001.47± 72.74
OG0011.18± 13.03
OG0021.34± 11.77
OG003
Tisotumab Vedotin: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
Title
Denominators
Categories
Tisotumab Vedotin: Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
Title
Measurements
OG00012.22± 11.61
OG00129.53± 4.08
OG00233.72± 6.26
OG003
Tisotumab Vedotin: Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 1
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
Total HuMax-TF: Cycle 2
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG0006.20± 72.05
OG00112.61± 28.18
OG00212.22± 67.23
OG003
Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0002
OG0011
OG0022
OG0031
OG0042
OG0051
OG0061
OG0071
Title
Denominators
Categories
Cycle 1
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0022
ParticipantsOG0031
ParticipantsOG0042
ParticipantsOG0051
ParticipantsOG0061
ParticipantsOG0071
Title
Measurements
OG00012.63± 12.44
OG00113.93± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00216.32± 57.56
OG003
Cycle 2
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0031
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG0000.760± 62.505
OG0011.673± 30.756
OG0021.524± 54.491
OG003
Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
PK was only planned to be analyzed per the dose level received, not per cancer type. So the PK data is pooled for all participants in the dose expansion part of the study.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG008168
Title
Denominators
Categories
Cycle 1
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG00023.88± 4.41
OG00122.77± 16.56
OG00224.39± 7.72
OG003
Cycle 2
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0002
OG0011
OG0022
OG0031
OG0042
OG0051
OG0061
OG0071
Title
Denominators
Categories
Cycle 1
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0022
ParticipantsOG0031
ParticipantsOG0042
ParticipantsOG0051
ParticipantsOG0061
ParticipantsOG0071
Title
Measurements
OG00095.15± 25.74
OG00169.34± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00263.98± 2.24
OG003
Cycle 2
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0031
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0070
OG0081
OG0093
OG0100
OG0110
OG0121
OG0130
OG0141
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0031
OG0040
OG0052
OG0061
OG0073
OG002
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG003
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG004
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG005
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG006
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG00015
OG00155
OG00214
OG00315
OG00415
OG00536
OG00618
Title
Denominators
Categories
TEAEs
Title
Measurements
OG00015
OG00155
OG00214
OG00315
OG00415
OG00536
OG00618
Serious TEAEs
Title
Measurements
OG0007
OG00126
OG0025
OG003
Infusion-Related TEAEs
Title
Measurements
OG0001
OG0011
OG0021
OG003
CTCAE Grade >=3 TEAEs
Title
Measurements
OG0009
OG00130
OG0028
OG003
TEAEs Related to Study Drug
Title
Measurements
OG00015
OG00154
OG00213
OG003
OG003
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG004
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG005
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG006
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG00014
OG00150
OG00212
OG00311
OG00414
OG00533
OG00612
Title
Denominators
Categories
Title
Measurements
OG0006.00(-127.0 to 41.0)
OG001-8.50(-64.0 to 50.0)
OG0021.00(-11.0 to 26.0)
OG003-2.00(-51.0 to 40.0)
OG0040.00(-59.0 to 31.0)
OG005-4.00(-41.0 to 115.0)
OG006-1.00(-11.0 to 15.0)
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0011
OG0020
OG0031
OG0041
OG0050
OG0060
OG0070
OG00811
Title
Denominators
Categories
Title
Measurements
OG00164.35(64.35 to 64.35)
OG00340.91(40.91 to 40.91)
OG0043.92(3.92 to 3.92)
OG00860.07(3.4 to 996.5)
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0mg/kg of body weight.
OG009
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0031
OG0040
OG0051
OG0061
OG0072
OG0088
OG00910
OG0103
OG01125
Title
Denominators
Categories
Title
Measurements
OG00318.75(18.75 to 18.75)
OG005-13.98(-13.98 to -13.98)
OG006113.71(113.71 to 113.71)
OG00711.62(-22.7 to 45.9)
OG008-25.17(-88.7 to 240.5)
OG00937.85(-46.1 to 666.2)
OG010180.94(47.1 to 980.5)
OG01173.19(-89.0 to 1924.4)
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Title
Measurements
OG0000(0 to 71)
OG0010(0 to 71)
OG0020(0 to 71)
OG00333(1 to 91)
OG0040(0 to 71)
OG0050(0 to 71)
OG0060(0 to 71)
OG0070(0 to 46)
OG00827(8 to 55)
OG00924(13 to 37)
OG0107(0 to 34)
OG01113(2 to 40)
OG01213(2 to 40)
OG01314(5 to 29)
OG0140(0 to 19)
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
OG0063
OG0076
OG00815
OG00955
OG01014
OG01115
OG01215
OG01336
OG01418
Title
Denominators
Categories
Week 6
Title
Measurements
OG0000(0 to 71)
OG00133(1 to 91)
OG00233(1 to 91)
OG00367(9 to 99)
OG00433(1 to 91)
OG005100(29 to 100)
OG00667(9 to 99)
OG00750(12 to 88)
OG00847(21 to 73)
OG00960(46 to 73)
OG01064(35 to 87)
OG01140(16 to 68)
OG01260(32 to 84)
OG01372(55 to 86)
OG01461(36 to 83)
Week 12
Title
Measurements
OG0000(0 to 71)
OG00133(1 to 91)
OG00233(1 to 91)
OG003
Week 24
Title
Measurements
OG0000(0 to 71)
OG00133(1 to 91)
OG0020(0 to 71)
OG003
Week 36
Title
Measurements
OG0000(0 to 71)
OG00133(1 to 91)
OG0020(0 to 71)
OG003
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0003
OG0013
OG0022
OG0032
OG0043
OG0052
OG0063
OG0073
OG00810
OG00941
OG0104
OG01110
OG0129
OG01326
OG01412
Title
Denominators
Categories
Title
Measurements
OG0005.1(4.9 to 5.4)
OG0016.0(3.9 to 49.1)
OG0026.1(4.9 to NA)Upper limit was not estimable because of insufficient number of participants with events prior to censoring.
OG00327.1(6.0 to NA)Upper limit was not estimable because of insufficient number of participants with events prior to censoring.
OG0046.1(5.3 to 10.4)
OG00517.1(11.3 to NA)Upper limit was not estimable because of insufficient number of participants with events prior to censoring
OG00612.3(5.0 to 14.1)
OG00711.3(2.1 to 11.3)
OG00811.0(5.1 to 43.0)
OG00918.1(9.3 to 23.0)
OG010NA(5.1 to NA)Median and upper limit were not estimable because of insufficient number of participants with events prior to censoring.
OG01110.1(5.3 to 17.0)
OG01213.0(5.1 to 17.3)
OG01313.0(12.1 to 18.3)
OG01412.9(7.1 to 23.7)
OG003
Dose Escalation Part: 1.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.
OG004
Dose Escalation Part: 1.5 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.
OG005
Dose Escalation Part: 1.8 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.
OG006
Dose Escalation Part: 2.0 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG007
Dose Escalation Part: 2.2 mg/kg
Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.
OG008
Dose Expansion Part: Bladder Cancer
Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG009
Dose Expansion Part: Cervical Cancer
Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG010
Dose Expansion Part: Endometrial Cancer
Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG011
Dose Expansion Part: Esophageal Cancer
Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG012
Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG013
Dose Expansion Part: Ovarian Cancer
Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
OG014
Dose Expansion Part: Prostate Cancer
Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0031
OG0040
OG0050
OG0060
OG0070
OG0084
OG00913
OG0101
OG0112
OG0122
OG0135
OG0140
Title
Denominators
Categories
Title
Measurements
OG003NA(NA to NA)Duration of response could not be estimated because DOR was censored for the single responder.
OG00832.0(11.0 to 32.0)
OG00918.4(13.1 to 41.7)
OG010NA(NA to NA)Duration of response could not be estimated because DOR was censored for the single responder.
OG01118.3(11.6 to 25.0)
OG012NA(12.0 to NA)Duration of response and the upper CI limit could not be estimated because DOR for one responder was censored later than the observed DOR for the other responder.
OG01321.4(13.1 to 29.6)
1 events
1 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events2 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events2 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0143 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0072 events2 affected6 at risk
EG0080 events0 affected15 at risk
EG0092 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0097 events6 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0095 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0136 events5 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events4 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events2 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0083 events3 affected15 at risk
EG0097 events5 affected55 at risk
EG0102 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0144 events3 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
3 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0074 events4 affected6 at risk
EG0087 events7 affected15 at risk
EG00930 events25 affected55 at risk
EG0108 events7 affected14 at risk
EG0118 events7 affected15 at risk
EG01216 events10 affected15 at risk
EG01330 events20 affected36 at risk
EG01414 events12 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0053 events2 affected3 at risk
EG0062 events1 affected3 at risk
EG0073 events3 affected6 at risk
EG0087 events6 affected15 at risk
EG00921 events19 affected55 at risk
EG0103 events3 affected14 at risk
EG0118 events6 affected15 at risk
EG0125 events5 affected15 at risk
EG01313 events11 affected36 at risk
EG01411 events9 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0063 events2 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events3 affected15 at risk
EG00926 events17 affected55 at risk
EG0108 events6 affected14 at risk
EG0114 events2 affected15 at risk
EG0124 events4 affected15 at risk
EG01319 events14 affected36 at risk
EG0147 events5 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0081 events1 affected15 at risk
EG00923 events18 affected55 at risk
EG0106 events4 affected14 at risk
EG0115 events4 affected15 at risk
EG0126 events6 affected15 at risk
EG01318 events11 affected36 at risk
EG0149 events6 affected18 at risk
3 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0082 events2 affected15 at risk
EG00917 events15 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events2 affected15 at risk
EG0139 events8 affected36 at risk
EG0148 events6 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events2 affected14 at risk
EG0112 events2 affected15 at risk
EG0122 events2 affected15 at risk
EG0134 events4 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events3 affected55 at risk
EG0106 events5 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0137 events6 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events3 affected55 at risk
EG0102 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0095 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events2 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0114 events4 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
4 events
3 affected
3 at risk
EG0043 events2 affected3 at risk
EG0054 events3 affected3 at risk
EG0062 events2 affected3 at risk
EG0075 events4 affected6 at risk
EG00813 events13 affected15 at risk
EG00940 events28 affected55 at risk
EG01013 events11 affected14 at risk
EG01110 events8 affected15 at risk
EG01215 events11 affected15 at risk
EG01334 events30 affected36 at risk
EG01412 events12 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events3 affected15 at risk
EG0098 events8 affected55 at risk
EG0103 events3 affected14 at risk
EG0112 events2 affected15 at risk
EG0123 events3 affected15 at risk
EG0137 events6 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0098 events5 affected55 at risk
EG0101 events1 affected14 at risk
EG0113 events3 affected15 at risk
EG0125 events5 affected15 at risk
EG0133 events3 affected36 at risk
EG0141 events1 affected18 at risk
2 events
2 affected
3 at risk
EG0041 events1 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0095 events5 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0136 events4 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0093 events3 affected55 at risk
EG0101 events1 affected14 at risk
EG0113 events3 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0136 events6 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0125 events2 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events3 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0123 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0053 events3 affected3 at risk
EG0060 events0 affected3 at risk
EG0074 events4 affected6 at risk
EG00810 events8 affected15 at risk
EG00934 events29 affected55 at risk
EG01012 events10 affected14 at risk
EG01110 events10 affected15 at risk
EG01211 events8 affected15 at risk
EG01318 events15 affected36 at risk
EG01416 events15 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0074 events4 affected6 at risk
EG0082 events2 affected15 at risk
EG00913 events11 affected55 at risk
EG0101 events1 affected14 at risk
EG0113 events2 affected15 at risk
EG0120 events0 affected15 at risk
EG0135 events4 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0071 events1 affected6 at risk
EG0081 events1 affected15 at risk
EG0095 events5 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events2 affected15 at risk
EG0135 events5 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0082 events1 affected15 at risk
EG0093 events3 affected55 at risk
EG0102 events2 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0137 events5 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0135 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0052 events2 affected3 at risk
EG0062 events2 affected3 at risk
EG0074 events4 affected6 at risk
EG0083 events3 affected15 at risk
EG00922 events22 affected55 at risk
EG0108 events8 affected14 at risk
EG0114 events4 affected15 at risk
EG0127 events7 affected15 at risk
EG01319 events19 affected36 at risk
EG0146 events6 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0085 events3 affected15 at risk
EG00911 events10 affected55 at risk
EG0103 events2 affected14 at risk
EG0113 events2 affected15 at risk
EG0121 events1 affected15 at risk
EG0137 events6 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0071 events1 affected6 at risk
EG0082 events1 affected15 at risk
EG0098 events7 affected55 at risk
EG0104 events4 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events2 affected15 at risk
EG0136 events6 affected36 at risk
EG0145 events4 affected18 at risk
2 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events2 affected15 at risk
EG0094 events4 affected55 at risk
EG0105 events4 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0072 events2 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events2 affected15 at risk
EG0121 events1 affected15 at risk
EG0136 events5 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0052 events2 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0089 events7 affected15 at risk
EG00937 events23 affected55 at risk
EG0108 events6 affected14 at risk
EG0115 events4 affected15 at risk
EG0127 events6 affected15 at risk
EG01319 events15 affected36 at risk
EG0149 events9 affected18 at risk
1 events
1 affected
3 at risk
EG0042 events1 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0073 events2 affected6 at risk
EG0083 events2 affected15 at risk
EG00916 events11 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0136 events4 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0133 events3 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0134 events4 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0103 events3 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events3 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0087 events6 affected15 at risk
EG00919 events16 affected55 at risk
EG0105 events5 affected14 at risk
EG0112 events2 affected15 at risk
EG0123 events3 affected15 at risk
EG01312 events10 affected36 at risk
EG0143 events3 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events1 affected15 at risk
EG0095 events5 affected55 at risk
EG0103 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0139 events9 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0097 events5 affected55 at risk
EG0103 events3 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events1 affected15 at risk
EG0136 events5 affected36 at risk
EG0143 events3 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0142 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0133 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0143 events3 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0075 events5 affected6 at risk
EG0083 events3 affected15 at risk
EG00922 events20 affected55 at risk
EG0106 events5 affected14 at risk
EG0117 events6 affected15 at risk
EG0125 events5 affected15 at risk
EG01313 events12 affected36 at risk
EG01414 events10 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0072 events2 affected6 at risk
EG0082 events2 affected15 at risk
EG00914 events11 affected55 at risk
EG0102 events1 affected14 at risk
EG0112 events2 affected15 at risk
EG0122 events2 affected15 at risk
EG0136 events5 affected36 at risk
EG0143 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0096 events6 affected55 at risk
EG0101 events1 affected14 at risk
EG0113 events2 affected15 at risk
EG0120 events0 affected15 at risk
EG0134 events4 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events2 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events2 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0083 events3 affected15 at risk
EG0096 events5 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events2 affected15 at risk
EG0121 events1 affected15 at risk
EG0139 events9 affected36 at risk
EG0145 events5 affected18 at risk
2 events
2 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0062 events2 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0096 events6 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0137 events6 affected36 at risk
EG0145 events4 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0083 events1 affected15 at risk
EG0097 events6 affected55 at risk
EG0102 events2 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events2 affected15 at risk
EG0133 events3 affected36 at risk
EG0145 events5 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0097 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0124 events3 affected15 at risk
EG0135 events4 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0101 events1 affected14 at risk
EG0112 events2 affected15 at risk
EG0122 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0082 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0123 events2 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events2 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG00914 events14 affected55 at risk
EG0106 events6 affected14 at risk
EG0112 events2 affected15 at risk
EG0127 events6 affected15 at risk
EG0136 events6 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0113 events3 affected15 at risk
EG0123 events2 affected15 at risk
EG0135 events5 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0094 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0135 events5 affected36 at risk
EG0141 events1 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0122 events2 affected15 at risk
EG0136 events6 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0094 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0095 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0135 events5 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events3 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0123 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0133 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0074 events3 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0052 events2 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0084 events4 affected15 at risk
EG00910 events9 affected55 at risk
EG0104 events4 affected14 at risk
EG0112 events2 affected15 at risk
EG0122 events2 affected15 at risk
EG0133 events3 affected36 at risk
EG0146 events6 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0081 events1 affected15 at risk
EG0099 events6 affected55 at risk
EG0105 events3 affected14 at risk
EG0113 events3 affected15 at risk
EG0122 events2 affected15 at risk
EG0132 events2 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0072 events2 affected6 at risk
EG0080 events0 affected15 at risk
EG0098 events7 affected55 at risk
EG0103 events3 affected14 at risk
EG0113 events3 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events1 affected14 at risk
EG0113 events3 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0095 events4 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0142 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0103 events3 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0052 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0103 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0122 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0112 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0102 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0054 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0091 events1 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
2 events
2 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0061 events1 affected3 at risk
EG0073 events3 affected6 at risk
EG0081 events1 affected15 at risk
EG00917 events13 affected55 at risk
EG0102 events2 affected14 at risk
EG0114 events3 affected15 at risk
EG0122 events2 affected15 at risk
EG0130 events0 affected36 at risk
EG0146 events3 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0051 events1 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0093 events3 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0133 events3 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0082 events2 affected15 at risk
EG0096 events6 affected55 at risk
EG0102 events2 affected14 at risk
EG0111 events1 affected15 at risk
EG0124 events4 affected15 at risk
EG0137 events6 affected36 at risk
EG0142 events2 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0123 events3 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0132 events2 affected36 at risk
EG0141 events1 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0061 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0111 events1 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0101 events1 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0070 events0 affected6 at risk
EG0081 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0121 events1 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0062 events1 affected3 at risk
EG0070 events0 affected6 at risk
EG0080 events0 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0130 events0 affected36 at risk
EG0140 events0 affected18 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected3 at risk
EG0050 events0 affected3 at risk
EG0060 events0 affected3 at risk
EG0071 events1 affected6 at risk
EG0082 events1 affected15 at risk
EG0090 events0 affected55 at risk
EG0100 events0 affected14 at risk
EG0110 events0 affected15 at risk
EG0120 events0 affected15 at risk
EG0131 events1 affected36 at risk
EG0140 events0 affected18 at risk
1.84
± 20.59
OG0051.17± 60.05
OG0061.56± 34.12
OG0070.87± 8.93
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG0011.72± 4.98
OG0021.44± 6.32
OG0031.07± 10.45
OG0042.05± 26.80
OG0050.93± 24.03
OG0061.30± 19.06
OG0071.03± 11.34
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0075
Title
Measurements
OG0011.02± 0.20
OG0020.98± 16.90
OG0030.69± 12.61
OG0041.26± 31.29
OG0050.81± 69.72
OG0060.87± 33.85
OG0070.56± 14.13
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG0011.05± 9.95
OG0020.98± 6.52
OG0030.71± 13.41
OG0041.40± 31.39
OG0050.53± 12.41
OG0060.82± 26.45
OG0070.61± 9.72
86.10
± 12.38
OG00581.13± 35.60
OG00692.04± 21.62
OG00761.46± 18.07
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00176.69± 9.53
OG00269.74± 7.99
OG00362.61± 6.03
OG00499.20± 20.82
OG00570.21± 42.93
OG00674.82± 4.19
OG00772.74± 5.79
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0075
Title
Measurements
OG00151.55± 1.61
OG00260.27± 17.79
OG00357.38± 8.65
OG00477.55± 10.74
OG00567.26± 50.61
OG00668.69± 30.52
OG00750.69± 7.20
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00155.75± 10.80
OG00257.13± 8.90
OG00358.48± 12.66
OG00484.98± 22.85
OG00550.62± 36.02
OG00660.40± 17.48
OG00758.10± 12.31
45.2
± 9.3
OG00433.1± 19.0
OG00563.0± 49.3
OG00652.3± 33.1
OG00784.9± 33.7
OG00879.31± 49.40
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0002.0± 15.7
OG0019.9± 49.1
OG00225.6± 7.1
OG00345.2± 10.1
OG00429.8± 25.1
OG00542.7± 72.7
OG00662.7± 21.5
OG00786.3± 14.4
OG00868.54± 55.49
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG0002.9± 0.5
OG00115.4± 53.1
OG00235.0± 18.9
OG00360.4± 13.4
OG00444.9± 27.8
OG00586.7± 54.3
OG00685.9± 36.7
OG007123.0± 34.7
OG008112.70± 45.23
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0002.4± 12.3
OG00114.4± 55.4
OG00235.7± 7.1
OG00358.8± 15.5
OG00440.9± 26.2
OG00560.2± 76.6
OG00692.5± 33.4
OG007133.6± 13.9
OG008114.54± 45.83
33.95
± 20.93
OG00563.88± 48.61
OG00653.47± 30.88
OG007105.84± 8.68
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00114.52± 4.98
OG00226.12± 6.44
OG00346.59± 9.98
OG00430.56± 26.43
OG00580.59± 24.03
OG00664.10± 19.06
OG00788.95± 11.04
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0072
Title
Measurements
OG00123.75± 0.20
OG00237.02± 16.39
OG00369.96± 13.26
OG00448.19± 35.67
OG00590.08± 52.74
OG00693.29± 30.45
OG007157.81± 12.70
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00123.01± 9.95
OG00237.08± 6.37
OG00367.93± 14.25
OG00443.41± 30.31
OG005136.08± 12.41
OG00698.59± 26.45
OG007145.82± 9.42
34.67
± 18.48
OG00423.12± 21.10
OG00535.42± 39.20
OG00632.30± 22.08
OG00755.53± 10.31
OG00829.1± 34.1
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0003.85± 27.65
OG00112.51± 11.51
OG00220.25± 5.14
OG00332.38± 7.11
OG00421.84± 24.97
OG00535.92± 30.39
OG00644.30± 0.32
OG00748.79± 26.37
OG00826.1± 41.2
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG0004.90± 13.00
OG00111.84± 8.31
OG00217.98± 11.64
OG00329.30± 10.14
OG00423.55± 25.16
OG00530.57± 37.42
OG00638.78± 21.77
OG00758.02± 12.77
OG00839.8± 31.1
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0003.96± 21.83
OG00111.54± 8.83
OG00216.90± 1.57
OG00331.33± 8.13
OG00422.11± 21.03
OG00537.71± 42.96
OG00643.40± 6.67
OG00753.67± 19.75
OG00838.3± 33.3
1.15
± 11.66
OG0041.12± 9.55
OG0051.18± 14.30
OG0061.18± 7.45
OG0071.11± 12.52
OG0081.21± 364.12
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0001.54± 63.29
OG0011.34± 6.27
OG0021.32± 5.96
OG0031.13± 11.18
OG0041.21± 16.61
OG0052.44± 35.75
OG0061.14± 9.29
OG0071.29± 7.55
OG0081.44± 303.89
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
ParticipantsOG008168
Title
Measurements
OG0002.20± 49.15
OG0011.18± 13.03
OG0021.34± 11.77
OG0031.15± 11.66
OG0041.12± 9.55
OG0051.18± 14.30
OG0061.18± 7.45
OG0071.11± 12.52
OG0081.10± 397.92
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008146
Title
Measurements
OG0002.19± 46.56
OG0011.34± 6.27
OG0021.32± 5.96
OG0031.13± 11.18
OG0041.21± 16.61
OG0051.76± 50.43
OG0061.14± 9.29
OG0071.29± 7.55
OG0081.15± 356.23
41.06
± 6.85
OG00432.42± 20.05
OG00547.89± 25.82
OG00640.93± 11.48
OG00741.19± 34.02
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00013.54± 5.50
OG00123.50± 39.89
OG00233.68± 1.74
OG00340.44± 4.69
OG00433.62± 14.50
OG00532.15± 62.74
OG00639.89± 23.15
OG00748.93± 5.61
ParticipantsOG0043
ParticipantsOG0053
ParticipantsOG0063
ParticipantsOG0076
Title
Measurements
OG00016.05± 27.93
OG00128.66± 30.64
OG00242.52± 7.48
OG00357.37± 8.65
OG00442.72± 34.62
OG00557.72± 17.47
OG00654.95± 5.32
OG00755.10± 27.36
ParticipantsOG0043
ParticipantsOG0052
ParticipantsOG0062
ParticipantsOG0073
Title
Measurements
OG00018.34± 8.73
OG00130.71± 27.65
OG00240.37± 4.27
OG00356.77± 9.60
OG00442.18± 25.39
OG00546.24± 53.11
OG00651.06± 9.18
OG00766.05± 10.07
11.63
± 52.69
OG00426.55± 44.24
OG00522.55± 57.26
OG00667.42± 59.98
OG00726.47± 59.35
OG00825.80± 93.91
Participants
OG004
3
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008145
Title
Measurements
OG0003.19± 140.85
OG0014.69± 87.27
OG00214.89± 66.97
OG00316.92± 58.12
OG00421.51± 34.25
OG00518.97± 52.14
OG00636.20± 33.82
OG00737.50± 43.08
OG00823.48± 76.47
20.39
± NA
Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00427.08± 58.96
OG00525.29± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00678.31± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00763.03± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
Participants
OG004
1
ParticipantsOG0051
ParticipantsOG0060
ParticipantsOG0071
Title
Measurements
OG00222.32± 43.62
OG00331.40± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00431.43± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00533.23± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00758.95± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
1.410
± 19.149
OG0042.807± 39.398
OG0052.587± 29.172
OG0066.351± 61.505
OG0074.877± 31.350
OG0083.16± 88.30
Participants
OG004
3
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008145
Title
Measurements
OG0001.091± 74.293
OG0011.342± 24.320
OG0022.059± 51.470
OG0032.243± 50.367
OG0042.718± 39.492
OG0052.035± 39.785
OG0063.369± 36.875
OG0074.704± 18.856
OG0082.73± 78.69
24.19
± 5.52
OG00425.07± 0.68
OG00547.74± 114.28
OG00683.24± 67.57
OG00784.88± 61.54
OG008154.28± 54.214
Participants
OG004
3
ParticipantsOG0053
ParticipantsOG0062
ParticipantsOG0073
ParticipantsOG008145
Title
Measurements
OG00023.73± 5.78
OG00124.05± 8.48
OG00223.92± 13.04
OG00324.94± 1.48
OG00425.26± 0.76
OG00546.24± 112.48
OG00665.15± 104.61
OG00747.12± 112.10
OG008125.38± 31.21
62.58
± NA
Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00463.65± 7.86
OG00578.90± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00657.74± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00768.47± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
Participants
OG004
1
ParticipantsOG0051
ParticipantsOG0060
ParticipantsOG0071
Title
Measurements
OG00269.65± 3.86
OG00360.71± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00470.20± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00578.94± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
OG00763.92± NAOnly 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.